Veru (NASDAQ:VERU – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Risk & Volatility
Veru has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Institutional and Insider Ownership
47.2% of Veru shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veru | 0 | 0 | 4 | 0 | 3.00 |
| MoonLake Immunotherapeutics | 0 | 2 | 9 | 0 | 2.82 |
Veru presently has a consensus price target of $4.00, indicating a potential upside of 373.65%. MoonLake Immunotherapeutics has a consensus price target of $80.45, indicating a potential upside of 64.39%. Given Veru’s stronger consensus rating and higher probable upside, equities analysts plainly believe Veru is more favorable than MoonLake Immunotherapeutics.
Profitability
This table compares Veru and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veru | -376.38% | -115.99% | -66.94% |
| MoonLake Immunotherapeutics | N/A | -10.61% | -10.36% |
Valuation & Earnings
This table compares Veru and MoonLake Immunotherapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veru | $14.09 million | 8.77 | -$93.15 million | ($0.34) | -2.48 |
| MoonLake Immunotherapeutics | N/A | N/A | -$36.01 million | ($0.75) | -65.25 |
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Veru. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Summary
MoonLake Immunotherapeutics beats Veru on 7 of the 13 factors compared between the two stocks.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
